Minerva Neurosciences, Inc. (NASDAQ:NERV) Files An 8-K Other Events
Item 8.01 Other Events.
On October 1, 2019, Minerva Neurosciences, Inc. (the Company) issued a press release providing updates regarding three of the Companys clinical trials. A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| 99.1 | Press Release of the Company dated October 1, 2019. |
Minerva Neurosciences, Inc. Exhibit
EX-99.1 2 d813246dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Contact: William B. Boni VP,…
To view the full exhibit click here
About Minerva Neurosciences, Inc. (NASDAQ:NERV)
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease. MIN-101 blocks serotonin receptors and sigma receptors, over two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-HT1A. MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen Pharmaceutica NV. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 protein.
